8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Methotrexate

**Essential medicine status**

**ATC codes:** L01BA01

**Indication**
Malignant trophoblastic neoplasms of placenta

**ICD11 code:** 2D25.0

**INN**
Methotrexate

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)

**EML status history**
First added in 2015 (TRS 994)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Methotrexate

**DrugBank**
Methotrexate

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methotrexate on the complementary list of the EML for use in treatment protocols for gestational trophoblastic neoplasia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for gestational trophoblastic neoplasia is attached.